{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=51", "query": { "intervention": "docetaxel", "page": 51 }, "page_size": 10 }, "pagination": { "page": 51, "page_size": 10, "total_count": 1321, "total_pages": 133, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=52&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=50&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T07:40:14.429Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00062270", "title": "Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gefitinib", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "19 Years to 120 Years" }, "enrollment_count": null, "start_date": "2003-05", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2015-10-08", "last_synced_at": "2026-10-31T07:40:14.429Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00062270" }, { "nct_id": "NCT07213674", "title": "A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Xaluritamig", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 750, "start_date": "2025-11-28", "completion_date": "2032-08-30", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-31T07:40:14.429Z", "location_count": 46, "location_summary": "Goodyear, Arizona • Tucson, Arizona • Duarte, California + 37 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07213674" }, { "nct_id": "NCT03737123", "title": "Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nabil Adra", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2018-12-19", "completion_date": "2022-05-18", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-31T07:40:14.429Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Omaha, Nebraska • Albuquerque, New Mexico + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03737123" }, { "nct_id": "NCT00617669", "title": "A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "ZD4054", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1494, "start_date": "2008-01", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2012-09-10", "last_synced_at": "2026-10-31T07:40:14.429Z", "location_count": 25, "location_summary": "Greenbrae, California • San Diego, California • Norwich, Connecticut + 22 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00617669" }, { "nct_id": "NCT06815497", "title": "Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Telmisartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyler J Curiel", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 33, "start_date": "2026-01-21", "completion_date": "2029-05-14", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-10-31T07:40:14.429Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • Manchester, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Manchester", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT06815497" }, { "nct_id": "NCT00599313", "title": "Phase II Sunitinib Prog Met AIPC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Prostate Cancer" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 36, "start_date": "2007-03", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2018-10-25", "last_synced_at": "2026-10-31T07:40:14.429Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Torrington, Connecticut • Ocala, Florida + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Torrington", "state": "Connecticut" }, { "city": "Ocala", "state": "Florida" }, { "city": "Niles", "state": "Illinois" }, { "city": "Terre Haute", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00599313" }, { "nct_id": "NCT00415285", "title": "Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Docetaxel/Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgia Center for Oncology Research & Education", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 100, "start_date": "2006-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-02-13", "last_synced_at": "2026-10-31T07:40:14.429Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00415285" }, { "nct_id": "NCT00551759", "title": "Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2008-10-02", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-10-31T07:40:14.429Z", "location_count": 109, "location_summary": "Lewes, Delaware • Newark, Delaware • Aurora, Illinois + 77 more", "locations": [ { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Aurora", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00551759" }, { "nct_id": "NCT00714246", "title": "Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 6, "start_date": "2008-10", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2019-06-24", "last_synced_at": "2026-10-31T07:40:14.429Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00714246" }, { "nct_id": "NCT05169684", "title": "A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [ { "name": "BMS-986218", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 10, "start_date": "2022-02-14", "completion_date": "2023-12-06", "has_results": true, "last_update_posted_date": "2025-06-10", "last_synced_at": "2026-10-31T07:40:14.429Z", "location_count": 25, "location_summary": "Tucson, Arizona • Los Angeles, California • Littleton, Colorado + 22 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169684" } ] }